BR112023017754A2 - Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmo - Google Patents
Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmoInfo
- Publication number
- BR112023017754A2 BR112023017754A2 BR112023017754A BR112023017754A BR112023017754A2 BR 112023017754 A2 BR112023017754 A2 BR 112023017754A2 BR 112023017754 A BR112023017754 A BR 112023017754A BR 112023017754 A BR112023017754 A BR 112023017754A BR 112023017754 A2 BR112023017754 A2 BR 112023017754A2
- Authority
- BR
- Brazil
- Prior art keywords
- indol
- treatment
- disorders
- related disorders
- useful
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003762 serotonin receptor affecting agent Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical class C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155634P | 2021-03-02 | 2021-03-02 | |
| PCT/CA2022/050295 WO2022183287A1 (en) | 2021-03-02 | 2022-03-02 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017754A2 true BR112023017754A2 (pt) | 2023-11-21 |
Family
ID=83153685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017754A BR112023017754A2 (pt) | 2021-03-02 | 2022-03-02 | Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240166630A1 (https=) |
| EP (2) | EP4301730A4 (https=) |
| JP (2) | JP2024508545A (https=) |
| KR (2) | KR20230154220A (https=) |
| CN (2) | CN117500788A (https=) |
| AU (2) | AU2022229037A1 (https=) |
| BR (1) | BR112023017754A2 (https=) |
| CA (2) | CA3210275A1 (https=) |
| IL (2) | IL305481A (https=) |
| MX (2) | MX2023010316A (https=) |
| WO (2) | WO2022183288A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20250053871A (ko) * | 2022-08-31 | 2025-04-22 | 사이빈 아이알엘 리미티드 | 트립타민 화합물, 조성물, 및 사용 방법 |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| CN121752545A (zh) * | 2023-11-06 | 2026-03-27 | 宜昌人福药业有限责任公司 | 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途 |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2025104490A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL170330B1 (pl) * | 1990-10-15 | 1996-11-29 | Pfizer | Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL |
| US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| DK1859798T3 (en) * | 2001-03-29 | 2016-03-21 | Lilly Co Eli | N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor |
| TWI318621B (en) * | 2006-08-03 | 2009-12-21 | Nat Bureau Of Controlled Drugs Dept Of Health | A series of deuterium labelled compounds as drug testing standards and their preparations |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| CN108484449A (zh) * | 2011-09-09 | 2018-09-04 | 蓝瑟斯医学影像公司 | 用于合成和使用显像剂的组合物、方法和系统 |
| WO2018094106A2 (en) * | 2016-11-16 | 2018-05-24 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| CA3132731A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| BR112022015379A2 (pt) * | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12240813B2 (en) * | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
-
2022
- 2022-03-02 AU AU2022229037A patent/AU2022229037A1/en active Pending
- 2022-03-02 KR KR1020237033368A patent/KR20230154220A/ko active Pending
- 2022-03-02 JP JP2023553660A patent/JP2024508545A/ja active Pending
- 2022-03-02 MX MX2023010316A patent/MX2023010316A/es unknown
- 2022-03-02 EP EP22762289.1A patent/EP4301730A4/en active Pending
- 2022-03-02 CN CN202280032370.6A patent/CN117500788A/zh active Pending
- 2022-03-02 WO PCT/CA2022/050296 patent/WO2022183288A1/en not_active Ceased
- 2022-03-02 BR BR112023017754A patent/BR112023017754A2/pt unknown
- 2022-03-02 MX MX2023010317A patent/MX2023010317A/es unknown
- 2022-03-02 EP EP22762290.9A patent/EP4301747A4/en active Pending
- 2022-03-02 AU AU2022229695A patent/AU2022229695A1/en active Pending
- 2022-03-02 CA CA3210275A patent/CA3210275A1/en active Pending
- 2022-03-02 WO PCT/CA2022/050295 patent/WO2022183287A1/en not_active Ceased
- 2022-03-02 IL IL305481A patent/IL305481A/en unknown
- 2022-03-02 CN CN202280032373.XA patent/CN117242065A/zh active Pending
- 2022-03-02 CA CA3210270A patent/CA3210270A1/en active Pending
- 2022-03-02 JP JP2023553664A patent/JP2024508922A/ja active Pending
- 2022-03-02 US US18/279,293 patent/US20240166630A1/en active Pending
- 2022-03-02 KR KR1020237033351A patent/KR20230154219A/ko active Pending
- 2022-03-02 US US18/279,290 patent/US20240166599A1/en active Pending
- 2022-03-02 IL IL305622A patent/IL305622A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3210270A1 (en) | 2022-09-09 |
| KR20230154219A (ko) | 2023-11-07 |
| MX2023010316A (es) | 2023-11-09 |
| EP4301747A1 (en) | 2024-01-10 |
| CA3210275A1 (en) | 2022-09-09 |
| WO2022183287A1 (en) | 2022-09-09 |
| KR20230154220A (ko) | 2023-11-07 |
| IL305622A (en) | 2023-11-01 |
| JP2024508545A (ja) | 2024-02-27 |
| US20240166630A1 (en) | 2024-05-23 |
| EP4301747A4 (en) | 2025-01-22 |
| WO2022183288A1 (en) | 2022-09-09 |
| AU2022229695A1 (en) | 2023-09-28 |
| AU2022229037A1 (en) | 2023-09-28 |
| EP4301730A4 (en) | 2025-01-22 |
| US20240166599A1 (en) | 2024-05-23 |
| EP4301730A1 (en) | 2024-01-10 |
| CN117500788A (zh) | 2024-02-02 |
| CN117242065A (zh) | 2023-12-15 |
| IL305481A (en) | 2023-10-01 |
| MX2023010317A (es) | 2023-11-09 |
| JP2024508922A (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023017754A2 (pt) | Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmo | |
| BR112022015379A2 (pt) | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc | |
| BR112022015375A2 (pt) | Derivados de psilocina como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc | |
| MX2023006652A (es) | Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc. | |
| BR112023002758A2 (pt) | Composições de oligossacarídeos de leite humano para uso com bacterioterapias | |
| BR112014011333A2 (pt) | derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares | |
| BRPI0510762A (pt) | derivados de tetraidronaftiridina úteis como ligantes do receptor de histamina h3 | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BR0315234A (pt) | Derivados de indol como agonistas beta-2 | |
| BRPI1007018B8 (pt) | composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. | |
| EA201190138A1 (ru) | Производные фуропиримидиндиона в качестве модуляторов trpa1 | |
| BRPI0408369A (pt) | derivados de indol úteis para o tratamento de doenças | |
| BR112015007818A2 (pt) | composto, composição farmacêutica, e, uso de um composto e de uma composição farmacêutica | |
| CL2010001363A1 (es) | Compuestos derivados de 1h-pirrolo[piridina o pirimidina], moduladores del receptores grucocorticoides; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento de enfermedades tales como diabetes tipo ii, obesidad e hipertension, entre otras | |
| CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| CR10387A (es) | Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor | |
| BR112021025136A2 (pt) | Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b | |
| BR112021024117A2 (pt) | Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| Kothandan et al. | Evaluation of in vitro antiviral activity of Vitex Negundo L., Hyptis suaveolens (L) poit., Decalepis hamiltonii Wight & Arn., to Chikungunya virus | |
| BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
| TW200637827A (en) | Processes for preparing substituted phenylpyrazole ureas | |
| BR112016006154A2 (pt) | derivados de indol e indazol | |
| NO20082679L (no) | Sammensetning og fremgangsmate for a behandle CNS lidelser |